Clinical Trial Update: Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study

View source ↗

Summary

An exploratory trial evaluating exhaled carbon monoxide as a marker of hemolysis in sickle cell disease has been withdrawn. The sponsor is University Hospitals …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: Sickle Cell Disease | Status: WITHDRAWN